Biocon Biologics Secures UK Nod for Denosumab Biosimilars Vevzuo & Evfraxy, Expands Bone Health Portfolio

Unknown Apr 02, 2026 950 Views

Biocon Biologics Ltd, a subsidiary of Biocon Ltd, has received marketing authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its Denosumab biosimilars—Vevzuo and Evfraxy. These approvals mark a significant milestone in Biocon’s expansion in...